Mesoblast Limited (ASX:MSB) Included In Standard And Poor/ASX 200 Index
Melbourne, April 18, 2011 AEST (ABN Newswire) - Standard and Poor's (S&P) Indices has announced that regenerative medicine company Mesoblast Limited (
ASX:MSB) (PINK:MBLTY) will be included in the S&P/ASX 200 Index, effective after the close of business on Wednesday 27 April, 2011.
"Inclusion in the S&P/ASX 200 index is a major achievement for Mesoblast," said Chief Executive Professor Silviu Itescu. "This important milestone serves to further underscore the company's strong financial performance and global leadership in the field of regenerative medicine."
About S&P/ASX 200
The S&P/ASX 200 is recognized as the primary investable benchmark in Australia. The index covers approximately 78% of Australian equity market capitalization. Index constituents are drawn from eligible companies listed on the Australian Securities Exchange. This index is designed to address investment managers' needs to benchmark against a portfolio characterized by sufficient size and liquidity.
About S&P Indices
S&P Indices, the world's leading index provider, maintains a wide variety of investable and benchmark indices to meet an array of investor needs. Over $1.25 trillion is directly indexed to Standard & Poor's family of indices.
Contact
Julie Meldrum
Corporate Communications Director
T: +61-3-9639-6036
C: +61-419-228-128
Email:julie.meldrum@mesoblast.com
| ||
|
